netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US
netscientific
netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US

G–Tech Medical completes $6.7m Series A financing

Jun 29, 2020
-
G -Tech Medical, News, RNS Announcements

NetScientific plc

(“NetScientific” or the “Company”)

G – Tech Medical, Inc. (“G – Tech”) announces completion of $6.7m Series A financing round led by DigiTx Partners

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.  

London, UK – 29 June 2020 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its venture portfolio company G – Tech Medical (“G – Tech”) today announced the completion of $6.7m Series A financing round led by DigiTx Partners.

NetScientific held a convertible loan note of $250,000, together with accrued interest, that had previously been fully impaired to £Nil. As part of the Series A financing the convertible loan note and interest converted to Series A Preferred Shares and Common Form Convertibles with a fair value, based on the financing round, in excess of £400,000. NetScientific now holds 3.8% of G – Tech’s fully diluted share capital.

G – Tech is developing a wearable medical technology that will be used to measure gastrointestinal motility.

 

Dr Iliev (Interim CEO of NetScientific) commented:

“This is a further example of the value lying in the NetScientific portfolio following the successful funding rounds in CytoVale, Inc., which in December 2019 raised $15 million in financing, for technology enabling early sepsis detection in the emergency department, valuing NetScientific’s interest, which had previously been written off, at £380,000; and Epibone, Inc., which in January 2020 raised a $8 million series seed round, at which point NetScientific converted a convertible loan note of $250,000 plus interest into an equity investment valued at £324,000.”

# # #

About G – Tech Medical, Inc.

G-Tech is developing a wearable medical technology that will be used to measure gastrointestinal (GI) motility. The G-Tech system will consist of wireless, wearable electrode patches that read electrical signals at the skin surface, a smartphone app that collects the raw data from the patches via Bluetooth LE and sends it to a cloud server, and data analysis algorithms that process and quantify the motor activity of the digestive organs. The system is currently under development.

The patches will be conforming, water resistant, thin, light and completely non-invasive. Although wearable and smartphone connected, the G-Tech system will be a medical device that will be used under the supervision of physicians rather than a consumer item.

G-Tech’s Patch System will be focused on meeting market driven and clinical needs to create a new standard of care that both dramatically improves outcomes and reduces costs associated with GI conditions. The system will have the potential to transform care for patients, providers and institutions. For further information see www.gtechmedical.com.

 

About DigiTx Partners

DigiTx Partners invests in and supports early to growth stage startup companies in the digital health space. We seek out innovative founders and leaders who are driving change across healthcare and life sciences ​through technology and meaningful data. For further information see https://www.digitxpartners.com

 

About CytoVale, Inc.

CytoVale is developing mechanical biomarkers to improve human health through probing individual cells to quantify the mechanical signatures of disease. The first target is sepsis, a condition whose early detection dramatically improves patient outcomes and reduces treatment cost, where CytoVale has enrolled a multi-hundred patient clinical study, which has the potential to significantly reduce morbidity and mortality, decrease healthcare costs, and satisfy a $1B+ diagnostic market. For further information see http://cytovale.com.

 

About Epibone, Inc.

EpiBone is a revolutionary bone reconstruction company that allows patients to “grow their own bone”. EpiBone’s pioneering technology utilizes a scan of the patient’s bone defect and the patient’s own stem cells to construct and cultivate a defect-specific autologous-like living bone graft. EpiBone is strategically positioned to provide a superior bone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year. For further information see https://www.epibone.com.

 

# # #

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Following the publication of this announcement, this inside information is now considered to be in the public domain.

For more information, please contact:

NetScientific

Ilian Iliev, CEO

Tel: +44 (0)20 3514 1800
WHIreland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel

Tel: +44 (0)20 7220 1666
MO PR ADVISORY (Press Contact)

Mo Noonan

Tel: +44 (0)78 7644 4977

 

About NetScientific

NetScientific PLC is a transatlantic healthcare IP commercialisation Group focused on technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people.

 

For more information, please visit the website at www.NetScientific.net

Share on FacebookShare on TwitterShare on Linkedin
← PREVIOUS POST
PDS collaborator awarded grant for Versamune
NEXT POST →
Holding(s) in Company

 

NetScientific plc

Level 39,
One Canada Square,
London, E14 5AB

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS & RNS Reach
  • Financial Results
  • Financial Calendar
  • Corporate Governance
  • News
  • Historic Material
Copyright
Terms of Use
G–Tech Medical completes $6.7m Series A financing - NetScientific
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT